Mirum Pharmaceuticals, Inc. (MIRM) Latest Company News

Oct 13, 2026, 15:45 UTC
Mirum Pharmaceuticals, Inc. announced that it plans to file Livmarli with the FDA in 2027.
Source:
- zacks.com
Oct 12, 2026, 12:01 UTC
Mirum Pharmaceuticals, Inc. shares rose 13%, boosted by research data.
Source:
- finance.sina.cn
Oct 12, 2026, 12:00 UTC
Mirum Pharmaceuticals, Inc. announced that the Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint in ultra-rare cholestatic liver diseases.
Source:
- businesswire.com
- zacks.com
Oct 11, 2026, 21:00 UTC
Mirum Pharmaceuticals, Inc. announced that it will host an investor call to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat).
Source:
- businesswire.com
Sep 28, 2026, 12:00 UTC
Mirum Pharmaceuticals announced that its Phase 3 AZURE-1 study of Brelovitug in chronic hepatitis delta virus met its primary endpoint.
Source:
Sep 27, 2026, 21:00 UTC
Mirum Pharmaceuticals announced it will host an investor call on September 28, 2026 to share topline results from the Phase 3 AZURE-1 study of Brelovitug in chronic hepatitis delta.
Source:
- businesswire.com
Sep 25, 2026, 23:00 UTC
The U.S. FDA approved Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva, as announced by Mirum Pharmaceuticals and Incyte.
Source:
- businesswire.com
- zacks.com
Sep 25, 2026, 19:02 UTC
The US Food and Drug Administration approved Mirum Pharmaceuticals' drug to treat a rare bone disorder.
Source:
- reuters.com
Sep 8, 2026, 12:36 UTC
Joanne Quan will step down as Chief Medical Officer of Mirum Pharmaceuticals, Inc., effective September 2, 2026, with Rob Myers appointed as her successor effective September 21, 2026.
Aug 25, 2026, 08:09 UTC
BlackRock Inc. disclosed a new stake of 4,390,063 shares in Mirum Pharmaceuticals, Inc., valued at approximately $513.95 million, representing about 7.20% ownership, in a recent SEC filing.
Source:
- defenseworld.net
Aug 5, 2026, 00:00 UTC
Mirum Pharmaceuticals reported Q2 2026 financial results with total revenue of $176.2 million, including Livmarli net product sales of $128.7 million and bile acid medicines net product sales of $47.5 million, and a net loss of $67.2 million.
Source:
Jun 14, 2026, 20:35 UTC
The U.S. FDA accepted the New Drug Application for zilurgisertib in fibrodysplasia ossificans progressiva under Priority Review.
Source:
Jun 14, 2026, 20:35 UTC
Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva.
Source:
- businesswire.com

MIRM

Mirum Pharmaceuticals, Inc. announced that it plans to file Livmarli with the FDA in 2027.

Mirum Pharmaceuticals, Inc. shares rose 13%, boosted by research data.

Mirum Pharmaceuticals, Inc. announced that the Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint in ultra-rare cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. announced that it will host an investor call to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat).

Mirum Pharmaceuticals announced that its Phase 3 AZURE-1 study of Brelovitug in chronic hepatitis delta virus met its primary endpoint.

Mirum Pharmaceuticals announced it will host an investor call on September 28, 2026 to share topline results from the Phase 3 AZURE-1 study of Brelovitug in chronic hepatitis delta.

The U.S. FDA approved Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva, as announced by Mirum Pharmaceuticals and Incyte.

The US Food and Drug Administration approved Mirum Pharmaceuticals' drug to treat a rare bone disorder.

Joanne Quan will step down as Chief Medical Officer of Mirum Pharmaceuticals, Inc., effective September 2, 2026, with Rob Myers appointed as her successor effective September 21, 2026.

BlackRock Inc. disclosed a new stake of 4,390,063 shares in Mirum Pharmaceuticals, Inc., valued at approximately $513.95 million, representing about 7.20% ownership, in a recent SEC filing.

Mirum Pharmaceuticals reported Q2 2026 financial results with total revenue of $176.2 million, including Livmarli net product sales of $128.7 million and bile acid medicines net product sales of $47.5 million, and a net loss of $67.2 million.

The U.S. FDA accepted the New Drug Application for zilurgisertib in fibrodysplasia ossificans progressiva under Priority Review.

Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva.